[Reuters] UnitedHealth: New hepatitis C drug costs far more than forecast

By Caroline Humer
April 17, 2014


UnitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was “multiple” times what it had expected.

UnitedHealth is the first insurer to quantify its costs to cover patients using Gilead’s new Sovaldi treatment, whose $84,000 price tag has spurred a national outcry over the rising costs of specialty medicines.


Read More



Sign-up for updates

  • This field is for validation purposes and should be left unchanged.